To include your compound in the COVID-19 Resource Center, submit it here.

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical fibrosis company that’s seeking up to $86.3 million in its proposed offering.

Launched by Third Rock Ventures in 2016, Pliant Therapeutics Inc. is developing lead candidate PLN-74809

Read the full 615 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE